Tracon Pharmaceuticals

TCON64

High Value

$0.12arrow_drop_down9.72%-$0.01

High Value

Penny Stock

TCON64

$0.12

arrow_drop_down9.72%-$0.01

High Value

Penny Stock

Performance History

Key Stats
Open	$0.12
Prev. Close	$0.13
EPS	5.93
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$215.36K

	LOW	HIGH
Day Range	0.12	0.12
52 Week Range	0.03	14.74

Ratios

Revenue	-





EPS	5.93

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Tracon Pharmaceuticals (TCON)

Tracon Pharmaceuticals Inc (TCON) is a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for cancer and age-related macular degeneration. The company's lead product candidate, TRC105, is being evaluated in multiple clinical trials for the treatment of solid tumors and wet age-related macular degeneration. TRC105 is a novel antibody that targets CD105, a protein that is highly expressed on the surface of tumor blood vessels and in the vasculature of the eye. By targeting CD105, TRC105 has the potential to disrupt the blood supply to tumors and prevent the growth and spread of cancer cells.

In addition to TRC105, Tracon has a pipeline of other product candidates, including TRC253, a small molecule inhibitor of the androgen receptor, which is being developed for the treatment of prostate cancer. The company also has a collaboration agreement with Santen Pharmaceutical Co., Ltd. to develop and commercialize TRC105 in wet age-related macular degeneration and other ophthalmic indications in Japan, Korea, and certain other Asian countries. Tracon Pharmaceuticals has a market cap of $XX billion and a PEG ratio of X.XX, which suggests that the stock may be undervalued compared to its industry peers.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Charles P. Theuer M.D., Ph.D.
Headquarters: San Diego
Employees: 18
Exchange: NASDAQ

Keep an eye on Tracon Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Tracon Pharmaceuticals 's (TCON) price per share?

The current price per share for Tracon Pharmaceuticals (TCON) is $0.12. The stock has seen a price change of -$0.01 recently, indicating a -9.73% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Tracon Pharmaceuticals (TCON)?

For Tracon Pharmaceuticals (TCON), the 52-week high is $14.74, which is 12.18K% from the current price. The 52-week low is $0.03, the current price is 252.94% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Tracon Pharmaceuticals (TCON) a growth stock?

Tracon Pharmaceuticals (TCON) has shown an average price growth of -6.65% over the past three years. It has received a score of 1 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Tracon Pharmaceuticals as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Tracon Pharmaceuticals (TCON) stock price performance year to date (YTD)?

As of the latest data, Tracon Pharmaceuticals (TCON) has a year-to-date price change of -96.61%. Over the past month, the stock has experienced a price change of 110.53%. Over the last three months, the change has been 20%. Over the past six months, the figure is -92.16%. Looking at a longer horizon, the five-year price change stands at -99.81%.

help

Is Tracon Pharmaceuticals (TCON) a profitable company?

Tracon Pharmaceuticals (TCON) has a net income of -$3.59M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -5.29K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , with a revenue growth rate of 33.83%, providing insight into the company's sales performance and growth. Operating income is noted at -$6.9M. Furthermore, the EBITDA is $6.12M.

help

What is the market capitalization of Tracon Pharmaceuticals (TCON)?

Tracon Pharmaceuticals (TCON) has a market capitalization of $215.36K. The average daily trading volume is 7.16K, indicating the stock's liquidity and investor engagement.